Genmab — November 2019
-
-
Janssen to test NKTR-255 in preclinical research studies
with therapies in Janssen’s oncology portfolio
■ Janssen responsible for the costs of the preclinical
studies
■ Nektar will contribute NKTR-255 for the studies and
cover the supply cost of its drug candidate
■ Nektar and Janssen will each maintain global
commercial rights to their respective drug candidates -
-
-
Vedr. donation: Ofte fremgår alias ikke på kontoudtog og jeg sidder ikke selv med dem i dagligdagen.
Send mig en mail på [email protected] ellers sms 28556430 med jeres alias, når I har foretaget en donation.
I kan også bruge beskedfunktionen her på sitet.
.
-
Først når jeg har et alias kan jeg tildele et Plus.
-
-
det virker lidt underligt, er da ret så betydeligt, men åbenbart ikke nok til en fondsbørsmeddelse
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind